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Treatments of multiple myeloma have significantly changed with improved
understanding of potential myeloma targets and have led to the era of novel
molecular-targeted antineoplastic agents, such as bortezomib and thalidomide.1
Bortezomib, an inhibitor of 26S proteosome, is a recently approved treatment
option for multiple myeloma.2 Thalidomide, a drug with immunomodulating and
antiangiogenic effects, along with anticytokine activity, has also shown promise
as an effective treatment in multiple myeloma. As novel treatments of multiple
myeloma become more frequent, physicians must be aware of the possible
toxicities. The reported common adverse effects of bortezomib and thalidomide
are asthenic conditions, gastrointestinal disturbances, and peripheral neuropathy.3
Pulmonary complications are believed to be uncommon, and interstitial lung
disease (ILD) is very rare.4 In this report, we describe a patient receiving bortezomib
and thalidomide in combination with dexamethasone for treatment-naïve multiple
myeloma in whom dyspnea and new pulmonary infiltrates developed, and whose
workup revealed a diagnosis of histologically-confirmed nonspecific interstitial
pneumonitis (NSIP).
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Bortezomib, an inhibitor of 26S proteosome, is recently approved treatment option for multiple myeloma.
Thalidomide, a drug with immunomodulating and antiangiogenic effects, has also shown promise as an effective
treatment in multiple myeloma. Pulmonary complications are believed to be rare, especially interstitial lung
disease. Here, we describe a patient with dyspnea and diffuse pulmonary infiltrates while receiving bortezomib
and thalidomide in combination with dexamethasone for treatment-naïve multiple myeloma. Bronchoalveolar
lavage demonstrated a significant decrease in the ratio of CD4 : CD8 T lymphocytes (CD4/8 ratio, 0.54).
Extensive workup for other causes, including infections, was negative. A lung biopsy under video-assisted
thorascopic surgery revealed a diagnosis of nonspecific interstitial pneumonitis. The symptoms and imaging
study findings improved after initiating steroid treatment. Physicians should be aware of this potential compli-
cation in patients receiving the novel molecular-targeted antineoplastic agents, bortezomib and thalidomide, who
present with dyspnea and new pulmonary infiltrates and fail to improve despite treatment with broad-spectrum
antibiotics.
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INTRODUCTION
A 67-year-old man was admitted because of back pain
caused by the compression fracture of the lumbar spines.
Serologic tests and bone marrow studies confirmed the
pathologic diagnosis of multiple myeloma, immunoglo-
bulin G (IgG) type. After he was diagnosed with multiple
myeloma at another hospital, he was referred to our hospital
for chemotherapy. In this frontline setting, a bortezomib-
based combination regimen was employed, consisting of
bortezomib administration at 1.3 mg/m2 on days 1, 4, 8,
and 11, thalidomide at 100 mg/day, and dexamethasone at
40 mg on days 1-4 and 8-11. After the completion of the
first 3-week cycle, he complained of mild dyspnea. He was
afebrile. A physical examination revealed fine crackles in
the bilateral upper lung fields. Room air arterial blood gas
analysis showed respiratory alkalosis (PaO2, 113 mmHg;
PaCO2, 19 mmHg). His chest radiograph showed mild
interstitial and reticular opacities in both lungs, and a high
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Fig. 1. Chest CT scans. (A and B) After the first cycle of triple regimen, at the time of clinical deterioration demonstrating newly developed
subpleural reticulation and diffuse interstitial changes in both upper and mid-lungs with a ground glass appearance. (C and D) Six weeks after
initiating the steroid treatment with marked improvement of interstitial pneumonitis.
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Fig. 2. Video-assisted thoracoscopic lung biopsy photomicrographs (Hematoxylin Eosin staining). (A) Alveolar walls are thickened with diffuse
interstitial fibrosis (original magnification ×12). (B) Interstitial fibrosis with characteristic temporal monogeneity is present with associated chronic
interstitial inflammation, whereas fibroblastic foci are not seen (original magnification ×100).
A B
resolution chest CT demonstrated newly developed sub-
pleural reticulation and diffuse interstitial changes in both
the upper and mid-lungs with a ground glass appearance
(Fig. 1A and B). Although lung complications are not
common with the use of the novel antineoplastic agents,
treatment with the second cycle was discontinued on day 7
for possible drug-induced interstitial pneumonitis. Simulta-
neously, broad-spectrum antibiotics were administered
because of his immunocompromised status.
Results of bronchoalveolar lavage (BAL) showed a signi-
ficantly decreased ratio of CD4 : CD8 T lymphocytes
(CD4/8 ratio, 0.54), and transbronchial lung biopsy showed
mild interstitial fibrosis. A microbial culture obtained from
BAL provided no evidence of bacterial, viral, or fungal
pathogens. Subsequently, wedge resection of the upper and
middle lobes of the right lung was carried on under video-
assisted thoraco-scopic surgery (VATS), and he was diag-
nosed as NSIP (Fig. 2). Within six weeks of steroid treat-
ment, follow-up chest radiographs and high resolution
computed tomography (HRCT) revealed marked im-
provement of interstitial pneumonitis (Fig. 1C and D). The
steroid treatment was effective and its dosage was decreased
according to the tapering schedule at the time of discharge.
Previous clinical studies on bortezomib and thalidomide
have shown low incidences of pulmonary adverse effects,4
and few cases of severe pulmonary toxicity associated with
bortezomib and thalidomide have been reported. 
ILD induced by bortezomib and thalidomide is very
rare. Only one case of thalidomide-induced interstitial
pneumonitis5 and one case of bortezomib-induced inter-
stitial pneumonitis have been reported so far.6 None of the
previous two ILD cases were confirmed by biopsy, thus
the subtype is not known. Our case is therefore the first
case of histologically-confirmed NSIP associated with
bortezomib and thalidomide during multiple myeloma
treatment.
The mechanism of pulmonary toxicity associated with
bortezomib and thalidomide is unclear. Although the
precise mechanism of action of thalidomide is still uncer-
tain, together with its antiangiogenic activity, it appears to
have immunomodulatory and anticytokine effect and alter
the production and activity of cytokines. Since it is postu-
lated that bortezomib affects not only nuclear factor (NF)-
kB activity but also various signaling pathways, its meta-
bolites might cause cellular reactions associated with
pulmonary injuries in some patients.7 In vitro studies with
human liver microsomes indicate that bortezomib is
primarily oxidatively metabolized through the cytochrome
P450 family of enzymes. Although the biotransformation
occurs predominantly in the liver, the lung may be a site of
active drug metabolism as well, for the lung has cyto-
chrome P450 enzymes levels estimated at 10 to 15 percent
of that of the liver, including the lung-specific cytochrome
P450 enzymes. When bortezomib and thalidomide are
used together, the adverse effects might synergize and
result in severe pulmonary toxicity such as ILD.
In conclusion, we present the first case of histologically-
confirmed NSIP after the administration of bortezomib and
thalidomide. Physicians should be aware of this potential
complication in patients receiving the novel targeted anti-
neoplastic agents, bortezomib and thalidomide, who pre-
sent with dyspnea and new pulmonary infiltrates and fail to
improve despite treatment with broad-spectrum antibiotics.
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